New obesity standards focus on belly fat and body composition, affecting men and Asian individuals most dramatically ...

The drug’s efficacy “looks to be highly competitive” and potentially better than rival pills from Novo and Lilly, BMO Capital ...

Rules determining who gets access to semaglutide in India were written for different bodies with different cardiovascular ...

California says it leads with science and compassion. By cutting treatment for chronic obesity, it is doing the opposite. If ...

Rhythm Pharma (RYTM) surges on IMCIVREE sales growth and TRANSCEND data ahead of the March 20 FDA PDUFA decision—see risks, ...

The study highlights that after stopping GLP-1 medications, many patients resume treatment or try alternatives, influencing ...

A recent genetic study has found that nearly a quarter of how a child’s body mass index, or BMI, changes over time may be ...

A slow NHS rollout has so far limited wide-ranging eligibility, meaning many patients have turned to private healthcare.

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the ...

Eli Lilly said copycat versions of Zepbound that add B12 result in potentially dangerous impurities. The compounding industry ...

If middle-class Americans lose their jobs to AI, that could mean fewer cash sales of weight-loss drugs like Zepbound Eli ...

The therapy shows efficacy in improving diarrhea, abdominal pain in GLP-1, GLP-1/GIP-treated patients with diabetes and/or ...